A response letter to comments on "Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016".

Competing Interests: Conflict of interest statement S.D. reports institutional fees and non-financial support from Roche / Genentech; grants, institutional fees and non-financial support from Pfizer; institutional fees and non-financial support from Puma; grants, institutional fees and non-financial support from AstraZeneca; grants, institutional fees and non-financial support from Novartis; and institutional fees and non-financial support from Amgen. E.D. reports travel expenses from Pfizer, Novartis and Amgen and board memberships from Novartis and Pfizer. T.B. reports grants, personal fees and non-financial support from Novartis, Pfizer, AstraZeneca; personal fees from Seattle Genetics; and personal fees and non-financial support from Roche. D.P. reports personal fees from ROCHE, personal fees and non-financial support from AstraZeneca, and grants from MSD, outside the submitted work. M.R. reports other from Roche, Astra Zeneca, MSD, Pfizer, Daiichi Sankyo and Lilly. A.A. declares no conflict of interest.